Shares of Diploma PLC (LON:DPLM - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 4,695.21 ($62.92) and traded as high as GBX 5,330 ($71.43). Diploma shares last traded at GBX 5,276.95 ($70.72), with a volume of 658,915 shares traded.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on DPLM shares. Jefferies Financial Group increased their price objective on shares of Diploma from GBX 4,500 to GBX 5,200 and gave the company a "hold" rating in a research report on Thursday, September 11th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a GBX 4,440 target price on shares of Diploma in a report on Wednesday, August 6th. Berenberg Bank increased their price target on shares of Diploma from GBX 5,750 to GBX 6,350 and gave the company a "buy" rating in a report on Wednesday, September 10th. Finally, Shore Capital restated a "hold" rating and set a GBX 5,100 price objective on shares of Diploma in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of GBX 5,238.
Check Out Our Latest Report on DPLM
Diploma Price Performance
The firm has a market capitalization of £7.07 billion, a price-to-earnings ratio of 4,245.33, a P/E/G ratio of 2.82 and a beta of 0.75. The company's 50 day moving average is GBX 5,375.19 and its 200 day moving average is GBX 4,695.21. The company has a quick ratio of 0.80, a current ratio of 2.17 and a debt-to-equity ratio of 62.17.
Diploma Company Profile
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.